Company Description
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States.
The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.
The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial.
In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development.
The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation.
4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | David Kirn |
Contact Details
Address: 5858 Horton Street, Suite 455 EmeryVille, California 94608 United States | |
| Phone | 510 505 2680 |
| Website | 4dmoleculartherapeutics.com |
Stock Details
| Ticker Symbol | FDMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001650648 |
| CUSIP Number | 35104E100 |
| ISIN Number | US35104E1001 |
| Employer ID | 47-3506994 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Kirn M.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. John F. Milligan Ph.D. | Executive Chairman |
| Dr. Fariborz Kamal Ph.D. | President and Chief Operating Officer |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Officer |
| Dr. Robert Y. Kim M.B.A., M.D. | Chief Medical Officer |
| Theresa Janke | Co-Founder and Chief of Staff |
| Uneek Mehra | Chief Financial and Business Officer |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer and Corporate Secretary |
| Dr. An Song Ph.D. | Chief Development Officer |
| Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. | Senior Vice President and Therapeutic Area Head of Pulmonology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |